47% of people ≥12 years treated with ALPROLIX on demand during the B-LONG trial switched to ALPROLIX prophy during the B-YOND trial
90%
of adults and adolescents aged 12 and older
B-LONG trial (n=575/636)
75%
of kids aged 1 to 11
Kids B-LONG trial (n=45/60)
87%
of previously untreated patients aged 0.1 to 2
PUPs B-LONG trial (n=74/85)
84%
of adults and adolescents aged 12 and older
B-LONG trial (n=513/613)
89%
of kids aged 1 to 11
Kids B-LONG trial (n=47/53)
91%
of previously untreated patients aged 0.1 to 2
PUPs B-LONG trial (n=72/79)
47% of people ≥12 years treated with ALPROLIX on demand during the B-LONG trial switched to ALPROLIX prophy during the B-YOND trial
Indication
Important Safety Information